新一代药物洗脱支架依维莫司药物洗脱支架临床循证研究  

Clinical evidence-based study on new-generation drug-eluting stent:everolimus-eluting stents(Xience Ⅴ)

作　　者：高文俊[1] 刘文洁[1] 柯永胜[1] 

机构地区：[1]皖南医学院弋矶山医院心血管内科

出　　处：《中国临床药理学与治疗学》2009年第5期591-595,共5页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：经皮冠状动脉介入(percutaneous coronary intervention,PCI)自20世纪70年代末应用临床以来,已成为治疗冠心病主要手段之一。第一代药物洗脱支架(drug-eluting stent,DES)如雷帕霉素洗脱支架(Cypher)和紫杉醇洗脱支架(Taxus)的循证医学证据表明其与金属裸支架比较,能进一步改善PCI的早期疗效,并减少再狭窄的风险。第一代DES在停止双重抗血小板治疗后出现的潜在的支架晚期血栓形成,是第一代DES最大的安全性问题。新一代DES依维莫司药物涂层支架(Xience Ⅴ)具有优越的抗再狭窄疗效以及长期安全性。本文就依维莫司药物涂层支架(Xience Ⅴ)的临床循证研究作一介绍。Percutaneous coronary intervention （PCI） has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, first-generation drug-eluting stents （DES）, such as sirolimuseluting （Cypher） and paclitaxel-eluting stents （Taxus）, have further improved results of percutaneous coronary intervention by improving early results and reducing the risk of restenosis. There are currently debates on the safety of these first-generation DES, given the potential for late stent thrombosis which is a first-generation drug-eluting stent of the largest security issue, es-pecially after discontinuation of dual antiplatelet therapy. Next-generation DES such as everolimus-eluting stents （Xience V） holds the promise of superior antirestenosis efficacy as well as long-term safety. This review makes a presentation of the evidence-based clinical research according to everolimus-eluting stents （Xience V）.

关 键 词：冠状动脉疾病 依维莫司 经皮冠状动脉腔内成形术 支架 

分 类 号：R969[医药卫生—药理学] R543[医药卫生—药学]